Background Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined. 

Methods We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes.

Results Data were combined by means of a fixed-effects model. In the 42 trials, the mean age of the subjects was approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval [CI], 1.03 to 1.98; P=0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P=0.06).

Conclusions Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

GSK Sent Avandia Meta Analysis Before Publication

GlaxoSmithKline's Avandia is once again making the headlines after it was revealed that the peer...

Another Revelation on Avandia Risks

This new research raised the possibility that long-term treatment with Avandia could lead to...

Government Estimates 83,000 Heart Attacks Caused by...

According to a November 2007 report by the Senate Finance Committee, an analysis by FDA scientists...

Avandia Study Shows Increased Heart Risks or Death

Older patients who took Avandia had a higher risk of heart attacks, congestive heart failure and death...

Avandia a Big Risk to Your Heart

Joyce A. says she did not know that Avandia could cause so many health problems, at least she did not...

Avandia Starting to Sound a lot like Vioxx

Mark D. is fighting for justice on behalf of his brother, Grant, whose health has gone downhill since he...

Thanks and deep appreciation for all your work

Thanks and deep appreciation for all your work and expertise. We were able to afford many things with our settlement. Many, many thanks again and again. God bless you always.

—Thelma